The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Prior to joining Alembic, he was working with Lupin Limited for more than 11 years
Global Ayurveda Festival organising in Thiruvananthapuram from 1st to 5th December
Subscribe To Our Newsletter & Stay Updated
